| Code | CSB-RA615684MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Nelmastobart, targeting BTN1A1 (butyrophilin subfamily 1 member A1), a transmembrane glycoprotein belonging to the immunoglobulin superfamily. BTN1A1 is expressed on epithelial cells and antigen-presenting cells, where it plays a regulatory role in immune responses and T cell modulation. This protein is involved in lipid metabolism regulation and has been implicated in various pathological conditions, including inflammatory disorders and cancer. BTN1A1 expression patterns have been associated with tumor progression and immune evasion mechanisms in multiple malignancies, making it an important target for immunological research.
Nelmastobart represents an investigational therapeutic antibody designed to modulate BTN1A1-mediated immune regulation. This biosimilar antibody provides researchers with a valuable tool for investigating BTN1A1 biology, exploring its role in immune checkpoint pathways, and studying potential therapeutic interventions in oncology and immunology. The antibody enables detailed examination of BTN1A1 function in cellular signaling, immune cell interactions, and disease-associated mechanisms.
There are currently no reviews for this product.